Oct. 28, 2025
Contact: Brian Consiglio, consigliob@missouri.edu
Photo by Brian Consiglio
In the quest for more targeted lung cancer treatments, a researcher at the University of Missouri thinks the solution may lie in tiny bubble-shaped packages that cells use to talk to each other.
These microscopic messengers, called extracellular vesicles (EVs), are about 3,000 times thinner than a human hair and are released in the billions by nearly every cell in the body, including cancer cells. While EVs from healthy cells carry helpful instructions to keep the body healthy, EVs from cancer cells can spread harmful signals that drive tumor growth and resistance to treatment.
Now, a researcher at the University of Missouri is manipulating those harmful carriers to stop cancer in its tracks.
In a recent study, Akhil Srivastava, an assistant professor in the School of Medicine, found that EVs produced by cancer cells contain higher levels of a protein called CD81 compared to EVs produced by healthy cells, indicating that CD81 may play a role in helping cancer tumors spread. So, Srivastava put tiny pieces of genetic material called siRNA into lung cancer cells with instructions to stop producing the CD81 protein. By “silencing” this protein, the EVs these cancer cells produced actually helped shrink tumors, confirming that CD81 was likely playing a role in helping cancer tumors spread in the first place.
“Once we discover more about all the biomolecular information these EVs carry from one cell to another, we can engineer them to deliver the information we want them to deliver to certain cells,” Srivastava said. “Since chemotherapy kills both healthy cells and cancer cells, and expensive immunotherapy doesn’t work for all patients, there is a big desire for more targeted cancer therapies. We believe tiny EVs can play a huge role in the solution.”
Srivastava believes EVs do not just play a role in helping cancer spread, they can also be engineered to help treat cancer. Similar to labeling a package with a specific delivery address, Srivastava wants to harness EVs as a drug delivery system so that new cancer drugs can target cancer cells without harming healthy cells.
In a related study, Srivastava recently demonstrated this idea by loading tiny pieces of siRNA into modified EVs. These snippets of genetic code carried specific instructions to kill lung cancer cells without significantly harming healthy ones. In a preclinical model, the approach worked, highlighting the potential promise of EV manipulation as a new kind of treatment.
Srivastava said Mizzou’s unique, team-based environment makes breakthroughs such as this possible.
“Mizzou is the perfect place for this research because we have surgeons, veterinarians and bioengineers all on the same campus,” he said. “The interdisciplinary collaboration at Mizzou helps push this promising work forward, and with how important cancer research is, hopefully our efforts can help a lot of people one day.”
“Perturbed CD81 in lung-cancer-derived extracellular vesicles modifies its function in cancer pathophysiology” was published in Molecular Therapy Oncology.
